GI254023X
Based on 21 publication(s) in Google Scholar
GI254023X is a potent MMP9 and ADAM10 inhibitor with IC50s of 2.5 and 5.3 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.60%
- CAS No.: 260264-93-5
- Formula: C21H33N3O4
- Molecular Weight:391.50
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) GI254023X
More- Signal Transduct Target Ther. 2024 Oct 30;9(1):294. [Abstract]
- Cell. 2026 Jun 25;189(13):3883-3902.e23. [Abstract]
- Neuron. 2023 Jun 21;111(12):1898-1913.e5. [Abstract]
- Adv Sci (Weinh). 2024 Jul 2:e2402107. [Abstract]
- Cell Rep Med. 2025 Jun 17;6(6):102146. [Abstract]
- J Exp Med. 2023 Dec 4;220(12):e20230018. [Abstract]
- Cancer Lett. 2024 Mar 31:585:216674. [Abstract]
- Genes Dis. 2020 Nov 21;8(6):867-881. [Abstract]
- Mucosal Immunol. 2025 Sep 12:S1933-0219(25)00093-5. [Abstract]
- Elife. 2021 Sep 20;10:e67261. [Abstract]
- Respir Res. 2026 Mar 31;27(1):205. [Abstract]
- Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):2. [Abstract]
- Philos Trans R Soc Lond B Biol Sci. 2024 Jul 29;379(1906):20230481. [Abstract]
- Front Aging Neurosci. 2021 Apr 15;13:660249. [Abstract]
- Mediators Inflamm. 2019 Oct 31;2019:5306541. [Abstract]
- Sci Rep. 2026 Feb 15;16(1):9169. [Abstract]
- J Cancer. 2025 Feb 11;16(5):1736-1746. [Abstract]
- Traffic. 2023 Jan;24(1):20-33. [Abstract]
- Brain Hemorrhages. 2022 Dec;3(4):218. [Abstract]
- bioRxiv. 2025 Sep 21.
- Research Square Preprint. 2023 Nov 20.
-
Cell Imaging/Staining
-
WB
-
Flow Cytometry
-
RT-PCR
-
WB
Biological Activity
IC50: 2.5 nM (MMP9), 5.3 nM (ADAM10)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KM-H2 | IC50 |
10 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human KM-H2 cells assessed as reduction in pervanadate-induced soluble ULBP3 shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human KM-H2 cells assessed as reduction in pervanadate-induced soluble ULBP3 shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| KM-H2 | IC50 |
10 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human KM-H2 cells assessed as reduction in pervanadate-induced TNFalpha shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human KM-H2 cells assessed as reduction in pervanadate-induced TNFalpha shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| KM-H2 | IC50 |
10 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-17 in human KM-H2 cells assessed as reduction in pervanadate-induced soluble ALCAM shedding after 24 hrs by ELISA
Inhibition of ADAM-17 in human KM-H2 cells assessed as reduction in pervanadate-induced soluble ALCAM shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| KM-H2 | IC50 |
12 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human KM-H2 cells assessed as reduction in pervanadate-induced soluble MICB shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human KM-H2 cells assessed as reduction in pervanadate-induced soluble MICB shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| L-428 | IC50 |
10 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-17 in human L428 cells assessed as reduction in pervanadate-induced soluble ALCAM shedding after 24 hrs by ELISA
Inhibition of ADAM-17 in human L428 cells assessed as reduction in pervanadate-induced soluble ALCAM shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| L-428 | IC50 |
12 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human L428 cells assessed as reduction in pervanadate-induced soluble MICB shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human L428 cells assessed as reduction in pervanadate-induced soluble MICB shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| L-428 | IC50 |
15 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human L428 cells assessed as reduction in pervanadate-induced soluble ULBP3 shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human L428 cells assessed as reduction in pervanadate-induced soluble ULBP3 shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| L-428 | IC50 |
5 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human L428 cells assessed as reduction in pervanadate-induced TNFalpha shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human L428 cells assessed as reduction in pervanadate-induced TNFalpha shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| L-540 | IC50 |
10 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human L540 cells assessed as reduction in pervanadate-induced soluble ULBP3 shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human L540 cells assessed as reduction in pervanadate-induced soluble ULBP3 shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| L-540 | IC50 |
12 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human L540 cells assessed as reduction in pervanadate-induced soluble MICB shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human L540 cells assessed as reduction in pervanadate-induced soluble MICB shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
| L-540 | IC50 |
7 μM
Compound: GIX; GI254023X
|
Inhibition of ADAM-10 in human L540 cells assessed as reduction in pervanadate-induced TNFalpha shedding after 24 hrs by ELISA
Inhibition of ADAM-10 in human L540 cells assessed as reduction in pervanadate-induced TNFalpha shedding after 24 hrs by ELISA
|
[PMID: 26871660] |
In cellular assay 25 μM and even a concentration of 1 μM GI254023X strongly reduces constitutive RAGE shedding; also PACAP-inducing shedding of RAGE is significantly reduced. At a concentration of 100 nM, a slight inhibition of RAGE shedding is still observed. In in vitro assays with recombinant proteinases, GI254023X discriminates between ADAM17 (IC50=541 nM) and ADAM10 (IC50=5.3 nM)/MMP9 (IC50=2.5 nM)[1]. CXCL16 shedding is inhibited by ADAM protease inhibitors (e.g GI254023x). A2780 cells are incubated with the ADAM-10/ADAM-17 inhibitor TAPI-2, as well as the ADAM-10-selective inhibitor GI254023x, as the level of expressed ADAM-10 is on average 9.8-fold higher on mRNA level compare with ADAM-17. In addition, GI254023x also prevents CXCL16 shedding from the cell membrane and is even more potent than TAPI-2[2]. When apply the specific ADAM10 (α-secretase) inhibitor GI254023X (5 mM) to serum/glucose-deprived slices, PI counts are significantly increased in comparison with DMSO (carrier)-treated controls[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 260264-93-5
-
Appearance Solid
-
Molecular Weight 391.50
-
Formula C21H33N3O4
-
Color White to off-white
-
SMILES
O=C(N[C@H](C(NC)=O)C(C)(C)C)[C@@H]([C@@H](N(C=O)O)C)CCCC1=CC=CC=C1
-
Synonyms
GI4023; SRI028594
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Human adipose and umbilical cord mesenchymal stem cell-derived extracellular vesicles mitigate photoaging via TIMP1/Notch1. [Abstract]2024 Oct 30;9(1):294. PMID: 39472581
GI254023X purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Oct 30;9(1):294. [Abstract]
Luciferase-reporter assays of HES1 transcriptional activity in HDFs after UVB, FM (culture medium), EV, TIMP1, GI254023X (10 μM), and VPA treatment. After UVB, HDFs were incubated with ADAM10 inhibitor GI254023X for 2 h, and then cells were incubated with fibroblast medium for an additional 24 h.
-
Cell
Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis. [Abstract]2026 Jun 25;189(13):3883-3902.e23. PMID: 42143019 -
Neuron
Differential and substrate-specific inhibition of γ-secretase by the C-terminal region of ApoE2, ApoE3, and ApoE4. [Abstract]2023 Jun 21;111(12):1898-1913.e5. PMID: 37040764 -
Adv Sci (Weinh)
Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy. [Abstract]2024 Jul 2:e2402107. PMID: 38953306
GI254023X purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 2:e2402107. [Abstract]
Immunoblotting analysis of proteins extracted from MC38 cells, which were plated on CAFs‐derived ECM and pre‐stimulated with collagen I (20 µg/mL) for 18 h followed by treatment with CPT‐11 (20 µM) for 48 h alone, or along with inhibitor, GI254023X (20 µM) for 24 h.
-
Cell Rep Med
DDX5 super-enhancer promotes vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription. [Abstract]2025 Jun 17;6(6):102146. PMID: 40412383 -
J Exp Med
Host factor TIMP1 sustains long-lasting myeloid-biased hematopoiesis after severe infection. [Abstract]2023 Dec 4;220(12):e20230018. PMID: 37851372
GI254023X purchased from MedChemExpress. Usage Cited in: J Exp Med. 2023 Dec 4;220(12):e20230018. [Abstract]
Treatment scheme and representative FACS plots showing percentages of CD11b+ myeloid cells and B cells in the BM of GI254023X (100 mg/kg, ip, 7 days)-treated mice (n = 9) or vehicle-treated mice (n = 7).
GI254023X purchased from MedChemExpress. Usage Cited in: J Exp Med. 2023 Dec 4;220(12):e20230018. [Abstract]
Hes1 expression in human HSPCs. Human CD34+ HSPCs were cultured in medium with indicated stimuli for 5 h. Expression of Hes1 transcripts was determined by qRT-PCR. Induction fold of Hes1 is calculated as the ratio of Hes1 levels stimulated with DLL4 plus GI254023X (1 μM, 5 h) or TIMP1 to that with DLL4 alone. Symbols depict data from three independent experiments. * P < 0.05; ns, P > 0.05 (unpaired two-tailed Student’s t test). RU, relative unit.
-
Cancer Lett
Direct interaction of platelet with tumor cell aggravates hepatocellular carcinoma metastasis by activating TLR4/ADAM10/CX3cl1 axis. [Abstract]2024 Mar 31:585:216674. PMID: 38280480 -
Genes Dis
2020 Nov 21;8(6):867-881. PMID: 34522714
GI254023X purchased from MedChemExpress. Usage Cited in: Genes Dis. 2020 Nov 21;8(6):867-881. [Abstract]
Representative Western blots of CTF proteins in SH-SY5Y-APP cells pretreated with vehicle (DMSO), β-secretases inhibitor (LY2811376, 50 μM) or α-secretases inhibitor (GI254023X, 10 μM) in combination with DAPT (250 nM) for 1 h, then incubated with or without sulfuretin at 20 μM for 24 h.
-
Mucosal Immunol
Neutrophil ADAM10 promotes migration and inflammation in ARDS by modulating adhesion and chemokine signaling. [Abstract]2025 Sep 12:S1933-0219(25)00093-5. PMID: 40947020 -
Elife
Synaptotagmin 7 is targeted to the axonal plasma membrane through γ-secretase processing to promote synaptic vesicle docking in mouse hippocampal neurons. [Abstract]2021 Sep 20;10:e67261. PMID: 34543184 -
Respir Res
2026 Mar 31;27(1):205. PMID: 41917947 -
Invest Ophthalmol Vis Sci
Inhibitor of DNA-Binding 3 Is a Novel Regulator of Limbal Epithelial Cell Migration Via the EphA2/Akt Signaling Pathway. [Abstract]2025 Jul 1;66(9):2. PMID: 40590805 -
Philos Trans R Soc Lond B Biol Sci
Alpha-secretase inhibition impairs Group I metabotropic glutamate receptor-mediated protein synthesis, long-term potentiation and long-term depression. [Abstract]2024 Jul 29;379(1906):20230481. PMID: 38853546 -
Front Aging Neurosci
Nasal Delivery of D-Penicillamine Hydrogel Upregulates a Disintegrin and Metalloprotease 10 Expression via Melatonin Receptor 1 in Alzheimer's Disease Models. [Abstract]2021 Apr 15;13:660249. PMID: 33935689 -
Mediators Inflamm
miR-23b Negatively Regulates Sepsis-Induced Inflammatory Responses by Targeting ADAM10 in Human THP-1 Monocytes. [Abstract]2019 Oct 31;2019:5306541. PMID: 31780861 -
Sci Rep
Chronic inflammation promotes gastric cancer progression via ADAM10-mediated cleavage of CX3CL1. [Abstract]2026 Feb 15;16(1):9169. PMID: 41691064 -
J Cancer
ADAM10 is a key player in the diagnosis, prognosis and metastasis of non-small cell lung cancer (NSCLC). [Abstract]2025 Feb 11;16(5):1736-1746. PMID: 39991567 -
Traffic
AP2S1 regulates APP degradation through late endosome-lysosome fusion in cells and APP/PS1 mice. [Abstract]2023 Jan;24(1):20-33. PMID: 36412210 -
Brain Hemorrhages
2022 Dec;3(4):218. PMID: 36406202 -
-
Solvent & Solubility
DMSO : 100 mg/mL (255.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cell death is quantified based on plasma membrane permeabilization. When apply the ADAM10 (a-secretase) inhibitor GI254023X (5 mM), slices are cultured in serum-/glucose-free medium for 48 h containing the inhibitor or its respective carrier (DMSO) as control. Round circles of identical size (Ø 500mm) are positioned in equivalent locations within the CA1 region of each hippocampus image and all PI-stained cells are counted using software. Cell viability assays are performed with a commercial kit according to the manufacturer’s instructions. The assay quantitates ATP levels, an indicator of metabolically active cells, photometrically with a fluorescence plate reader. Additionally, the live-dead cell staining kit are applied according to the manual. Cells are simultaneously stained with green fluorescent calcein-AM (4mM; ex/em: 495/515 nm) to detect intracellular esterase activity (viable cells) and red fluorescent ethidium homodimer-3 (2mM; ex/em: 530/635 nm) to indicate loss of plasma membrane integrity (dead cells)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Verena V. Metz, et al. Induction of RAGE Shedding by Activation of G Protein-Coupled Receptors. PLoS One. 2012. [Content Brief]
[2]. M J M Gooden, et al. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. British Journal of Cancer (2014) 110, 1535–1544. [Content Brief]
[3]. N Milosch, et al. Holo-APP and G-protein-mediated signaling are required for sAPPa-induced activation of the Akt. Cell Death Dis. 2014 Aug 28;5:e1391. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5543 mL | 12.7714 mL | 25.5428 mL | 63.8570 mL |
| 5 mM | 0.5109 mL | 2.5543 mL | 5.1086 mL | 12.7714 mL | |
| 10 mM | 0.2554 mL | 1.2771 mL | 2.5543 mL | 6.3857 mL | |
| 15 mM | 0.1703 mL | 0.8514 mL | 1.7029 mL | 4.2571 mL | |
| 20 mM | 0.1277 mL | 0.6386 mL | 1.2771 mL | 3.1928 mL | |
| 25 mM | 0.1022 mL | 0.5109 mL | 1.0217 mL | 2.5543 mL | |
| 30 mM | 0.0851 mL | 0.4257 mL | 0.8514 mL | 2.1286 mL | |
| 40 mM | 0.0639 mL | 0.3193 mL | 0.6386 mL | 1.5964 mL | |
| 50 mM | 0.0511 mL | 0.2554 mL | 0.5109 mL | 1.2771 mL | |
| 60 mM | 0.0426 mL | 0.2129 mL | 0.4257 mL | 1.0643 mL | |
| 80 mM | 0.0319 mL | 0.1596 mL | 0.3193 mL | 0.7982 mL | |
| 100 mM | 0.0255 mL | 0.1277 mL | 0.2554 mL | 0.6386 mL |